Saint Luke's Mid America Heart Institute, Kansas City, Missouri; University of Missouri-Kansas City, Kansas City, Missouri.
Monash Heart, Melbourne, Australia.
JACC Cardiovasc Interv. 2017 Nov 13;10(21):2174-2181. doi: 10.1016/j.jcin.2017.08.043.
Few studies have evaluated the relationship of diabetes with technical success and periprocedural complications, and no studies have compared patient-reported health status after chronic total occlusion (CTO) percutaneous coronary intervention (PCI) in patients with and without diabetes.
CTOs are more common in patients with diabetes, yet CTO PCI is less often attempted in patients with diabetes than in patients without. The association between diabetes and health status after CTO PCI is unknown.
In the 12-center OPEN-CTO PCI registry (Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion Registry), patients with and without diabetes were assessed for technical success, periprocedural complications, and health status over 1 year following CTO PCI using the Seattle Angina Questionnaire and the Rose Dyspnea Scale. Hierarchical modified Poisson regression was used to examine the independent association between diabetes and technical success, and hierarchical multivariable linear regression was used to assess the association between diabetes and follow-up health status.
Diabetes was common (41.2%) and associated with a lower crude rate of technical success (83.5% vs. 88.1%; p = 0.04). After adjustment, there was no significant difference between diabetic and nondiabetic patients (relative risk: 0.96, 95% confidence interval: 0.91 to 1.01). There were no significant differences in complication rates between patients with and without diabetes. Angina burden, quality of life, and overall health status scores were similar between diabetic and nondiabetic patients over 1 year.
Although technical success was lower in patients with diabetes, this reflected lower success among patients with prior bypass surgery, without any significant difference in success rate after adjusting for prior bypass and disease complexity. CTO PCI complication rates are similar in diabetic and nondiabetic patients, and symptom improvement following CTO PCI is robust and of a similar magnitude regardless of diabetes status.
鲜有研究评估糖尿病与技术成功和围手术期并发症的关系,也没有研究比较有糖尿病和无糖尿病的慢性完全闭塞(CTO)经皮冠状动脉介入治疗(PCI)患者的患者报告健康状况。
CTO 在糖尿病患者中更为常见,但与无糖尿病患者相比,糖尿病患者接受 CTO PCI 的尝试较少。糖尿病与 CTO PCI 后健康状况之间的关系尚不清楚。
在 12 中心 OPEN-CTO PCI 注册研究(结局、患者健康状况和 CTO 注册中的效率)中,使用西雅图心绞痛问卷和玫瑰呼吸困难量表,在 CTO PCI 后 1 年评估有和无糖尿病患者的技术成功、围手术期并发症和健康状况。使用分层修正泊松回归检验糖尿病与技术成功之间的独立关联,使用分层多变量线性回归评估糖尿病与随访健康状况之间的关联。
糖尿病很常见(41.2%),且技术成功率较低(83.5%比 88.1%;p=0.04)。校正后,糖尿病患者和非糖尿病患者之间无显著差异(相对风险:0.96,95%置信区间:0.91 至 1.01)。糖尿病患者和非糖尿病患者的并发症发生率无显著差异。在 1 年的时间内,糖尿病患者和非糖尿病患者的心绞痛负担、生活质量和整体健康状况评分相似。
尽管糖尿病患者的技术成功率较低,但这反映了既往旁路手术患者成功率较低,在校正既往旁路和疾病复杂程度后,成功率无显著差异。糖尿病患者和非糖尿病患者的 CTO PCI 并发症发生率相似,并且 CTO PCI 后的症状改善是稳健的,且无论糖尿病状态如何,改善幅度相似。